Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Will Wedbush Upgrade to “Neutral” from “Underperform” Be a Tailwind For Spark Therapeutics (NASDAQ:ONCE) Stock Today?

Wedbush Analyst Rating Change Spark Therapeutics NASDAQ:ONCE

Spark Therapeutics (NASDAQ:ONCE) Rating Change

Spark Therapeutics (NASDAQ:ONCE) was boosted by Wedbush from “Underperform” rating to “Neutral” rating in analysts note shared with investors and clients on Wednesday, 13 December. The firm currently has a $50.0 target price on the stock. Wedbush’s target price means a potential downside of -38.20 % from the stock’s close price.

The rating upgrade is well received by stock speculators, as NASDAQ:ONCE is at the moment trading 0.11% higher at $74.11 as of 12:03 PM New York time. Spark Therapeutics’s stock is 0% in the last 200 days. It has underperformed the S&P 500 Index, which has gained 6.00% in the same time.

According to data compiled by Thomson Reuters, Spark Therapeutics (NASDAQ:ONCE)’s stock is covered by 9 equity analysts across the Street, with 1 analysts giving it a Sell rating, 5 a Buy rating, while 3 consider it a Hold. The 12-month consensus target price for the stock is $58.44, which reflects an downside potential of 21.14% over the current price.

Institutional Ownership

Rock Springs Capital Management Lp had the most significant stake with ownership of 625,000 shares as of q2 2015 for 2.35% of the US long stock exposure. Brookside Capital Management Llc is another bull as the investment manager who is having 367,314 shares of Spark Therapeutics or 1.43% of their US long stock exposure. Also, Ecor1 Capital Llc have 1.26% of their US long stock exposure invested in the company for 68,600 shares. The New York-based fund Deerfield Management Co revealed it had bought so far a stake worth about 1.03% of the investment manager’s stock portfolio in Spark Therapeutics. The New York-based fund Baker Bros. Advisors Lp is also positive about the stock, possessing 368,000 shares or 0.72% of their US long stock exposure.

Spark Therapeutics (NASDAQ:ONCE) Profile

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

Spark Therapeutics (NASDAQ:ONCE) traded up 0.11% on 13 December, hitting $74.11. A total of 177,872 shares of the company’s stock traded hands. This is down from average of 518,672 shares. Spark Therapeutics has a 52 week low of $47.03 and a 52 week high of $91.75. The company has a market cap of $2.74 billion and a P/E ratio of 0.

Get the latest Spark Therapeutics (NASDAQ:ONCE) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Will Wedbush Upgrade to “Neutral” from “Underperform” Be a Tailwind For Spark Therapeutics (NASDAQ:ONCE) Stock Today? appeared first on Octafinance.



This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Will Wedbush Upgrade to “Neutral” from “Underperform” Be a Tailwind For Spark Therapeutics (NASDAQ:ONCE) Stock Today?

×

Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription

×